Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061880 · ClinicalTrials.gov registry record · Phase 1
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase 1 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00061880 is a Phase 1 study that has completed, run by BioCryst Pharmaceuticals.
The verdict
NCT00061880, a Phase 1 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.
Interventions
- DRUG forodesine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061880
The ClinicalTrials.gov registry entry for NCT00061880 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which forodesine hydrochloride is the first listed.
NCT00061880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061880 about?
NCT00061880 is a clinical study titled "BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma". RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.
What is the current status of trial NCT00061880?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-02. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00061880?
The interventions under investigation include: forodesine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00061880?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.